XML 158 R64.htm IDEA: XBRL DOCUMENT
v3.20.4

Collaboration Agreements - Merck – Strategic Alliances in Infectious Diseases and Cancer Vaccines (Details) - USD ($) $ in Thousands |  |  | 1 Months Ended | 3 Months Ended | 12 Months Ended | 53 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | ---
May 21, 2020 | Feb. 14, 2020 | Apr. 30, 2018 | Jun. 30, 2016 | Jan. 31, 2016 | Jan. 31, 2015 | Dec. 31, 2020 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | May 31, 2019 | Jan. 01, 2019 | Jun. 30, 2017
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  | $ 3,842,307 | $ (44,119) | $ (65,260) |  |  |
Remaining performance obligations |  |  |  |  |  |  | $ 87,225 | 87,225 |  |  |  |  |
Increase to the transaction price |  |  |  |  |  |  |  | (7,100) |  |  |  |  |
Aggregate net proceeds from the offering | $ 1,300,000 | $ 549,500 |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  | 4,044,612 | 4,044,612 | 202,305 |  |  |  |
Additions |  |  |  |  |  |  |  | 4,009,960 |  |  |  |  |
Collaboration revenue |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  | 240,182 | 240,182 | 199,528 |  |  |  |
Additions |  |  |  |  |  |  |  | 121,882 |  |  |  |  |
Merck agreement 2015 |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  | $ 50,000 |  |
Proceeds from equity investment |  |  |  |  |  | $ 50,000 |  |  |  |  |  |  |
Initial research period |  |  |  |  |  |  |  |  |  |  | 4 years |  |
Remaining performance obligations |  |  |  |  |  |  | 52,647 | 52,647 | 59,735 |  |  | $ 65,000 |
Performance period |  |  |  |  |  |  |  |  |  |  | 3 years |  |
Increase to the transaction price |  |  |  |  |  |  |  | 12,353 | 5,265 |  |  |  |
Additions |  |  |  |  | $ 10,000 |  |  |  |  |  |  |  |
Merck agreement 2015 | Collaboration revenue |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue from contract with customer, excluding assessed tax |  |  |  |  |  |  |  | 62 | 492 | 24,582 |  |  |
Separate agreements with Merck | Collaboration revenue |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue from contract with customer, excluding assessed tax |  |  |  |  |  |  |  | (7,026) | (4,773) | 24,582 |  |  |
PCV Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Estimated arrangement consideration |  |  |  |  |  |  |  |  |  |  |  |  | $ 250,000
Additions |  |  |  | $ 200,000 |  |  |  |  |  |  |  |  |
PCV Agreement | Series H Redeemable Convertible Preferred Stock |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate net proceeds from the offering |  |  | $ 125,000 |  |  |  |  |  |  |  |  |  |
Premium recorded to deferred revenue |  |  | 13,000 |  |  |  |  |  |  |  |  |  |
PCV Agreement | PCV products |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Estimated arrangement consideration |  |  | $ 243,000 |  |  |  | 243,000 | 243,000 | 243,000 |  |  |  |
PCVSAV Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Remaining performance obligations |  |  |  |  |  |  | 213,360 | 213,360 | 213,050 |  |  |  |
Deferred revenue |  |  |  |  |  |  | 51,007 | 51,007 | 83,799 |  |  |  |
PCVSAV Agreement | Collaboration revenue |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue from contract with customer, excluding assessed tax |  |  |  |  |  |  |  | 33,103 | 41,382 | $ 41,498 |  |  |
Increase to the transaction price |  |  |  |  |  |  | 3,500 | 3,500 |  |  |  |  |
Upfront payment | Merck agreement 2015 |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Remaining performance obligations |  |  |  |  |  |  | 60,000 | 60,000 | 60,000 |  |  | 60,000 |
Upfront payment | PCVSAV Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Remaining performance obligations |  |  |  |  |  |  | 200,000 | 200,000 | 200,000 |  |  |  |
Milestone payment | Merck agreement 2015 |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue from contract with customer, excluding assessed tax |  |  |  |  |  |  |  |  |  |  | $ 5,000 |  |
Remaining performance obligations |  |  |  |  |  |  |  |  |  |  |  | $ 5,000 |
Premium associated with the contemporaneous sale of Series H redeemable convertible preferred stock | PCVSAV Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Remaining performance obligations |  |  |  |  |  |  | 13,050 | 13,050 | 13,050 |  |  |  |
Upfront Payment, Research And Development | Merck agreement 2015 |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Remaining performance obligations |  |  |  |  |  |  | 5,000 | 5,000 | $ 5,000 |  |  |  |
PCV Performance Obligation | PCVSAV Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Remaining performance obligations |  |  |  |  |  |  | 206,356 | 206,356 |  |  |  |  |
KRAS Performance Obligation | PCVSAV Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Remaining performance obligations |  |  |  |  |  |  | $ 7,004 | $ 7,004 |  |  |  |  |

X
- Definition Research And Development Arrangement, Contract To Perform For Others, Maximum Amount + References No definition available. + Details
Name: | mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount
Namespace Prefix: | mrna_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Research And Development Arrangement, Contract To Perform For Others, Performance Period + References No definition available. + Details
Name: | mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformancePeriod
Namespace Prefix: | mrna_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research And Development Arrangement, Contract To Perform For Others, Research Period + References No definition available. + Details
Name: | mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod
Namespace Prefix: | mrna_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 + Details
Name: | us-gaap_IncreaseDecreaseInContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585 + Details
Name: | us-gaap_ProceedsFromIssuanceOrSaleOfEquity
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The excess of the (1) fair value of consideration transferred to the holders of a security in excess of (2) the carrying amount of the security reported on the registrant's balance sheet, which will be deducted from net earnings to derive net earnings available to common shareholders. This amount is generally an adjustment considered in the computation of earnings per share. + References No definition available. + Details
Name: | us-gaap_RedemptionPremium
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Cash received on stock transaction after deduction of issuance costs. + References No definition available. + Details
Name: | us-gaap_SaleOfStockConsiderationReceivedOnTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_MerckAgreement2015Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_SeparateAgreementsWithMerckMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_PersonalizedMRNACancerVaccinesProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PCVSAVAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_UpfrontPaymentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_MilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_UpfrontPaymentPremiumAssociatedWithContemporaneousSaleOfPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_UpfrontPaymentResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | mrna_PerformanceObligationAxis=mrna_PCVPerformanceObligationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | mrna_PerformanceObligationAxis=mrna_KRASPerformanceObligationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |